IQVIA Holdings Inc stock (US46266C1053): shares advance after recent outlook hike and buyback support

IQVIA Holdings Inc shares on the NYSE traded higher toward the end of the week after investors continued to respond to the company’s raised 2026 profit outlook and a newly authorized share repurchase program, keeping the United States-based healthcare data specialist in focus.

IQVIA Holdings Inc shares continued to attract attention on the New York Stock Exchange on Friday as investors digested the company’s recently raised profit outlook and fresh share buyback authorization, which have helped the United States healthcare data and clinical research group recoup part of its earlier year-to-date decline.

The stock was quoted around USD 177 to USD 178 intraday, having closed the prior session at approximately USD 165.97 according to MarketBeat data as of 05/28/2026, with the move in recent days leaving IQVIA up more than 7% on the day at one point and roughly 30% higher over the past 12 months. A separate intraday snapshot from Robinhood around the current week showed the shares trading at about USD 178.10 with a market capitalization close to USD 29.7 billion and a price/earnings multiple of roughly 20.5, underscoring the scale of the rebound in the United States market.

Investor focus has been shaped by the company’s latest quarterly update, in which IQVIA raised its 2026 profit outlook and announced additional share repurchase capacity, developments that have been cited as key drivers behind a roughly 9.3% single-day gain earlier this week as tracked by Quiver Quantitative. The combination of stronger-than-expected adjusted earnings per share and a clearer capital returns framework has supported sentiment toward the New York-listed stock, even as broader US health care and data services names remain sensitive to interest-rate expectations and spending trends.

From a home-country perspective, IQVIA is firmly anchored in the United States, with its primary listing on the NYSE under the ticker IQV, and the stock’s moves feed directly into US-focused strategies that track healthcare and data-driven services holdings. For investors in Germany, the shares can also be accessed via secondary trading venues such as Tradegate, where prices are typically translated into euros and follow the lead from the US close, although liquidity and spreads tend to be lower than on the New York Stock Exchange.

The stock traded at 165.97 USD on 05/28/2026 on the New York Stock Exchange, according to MarketBeat as of 05/28/2026. Market data during Friday’s US session pointed to a continued firm tone in the shares as the market absorbs the higher 2026 profit outlook and buyback plans highlighted in recent commentary on the company’s fundamentals.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: IQVIA Holdings Inc
• Sector/industry: Healthcare data analytics, contract research and technology services
• Headquarters/country: Durham, United States
• Core markets: North America, Europe and selected Asia-Pacific healthcare and life sciences markets
• Key revenue drivers: Clinical research services, real-world data and analytics solutions, and technology-enabled commercialization support for biopharma clients
• Home exchange/listing venue: New York Stock Exchange (IQV)
• Trading currency: USD

IQVIA Holdings Inc: core business model

IQVIA operates as a data-rich healthcare services and technology provider, combining large-scale clinical research operations with software and analytics platforms that help biopharmaceutical and life sciences customers design trials, generate evidence and support commercialization decisions.

Valuation metrics and multiples for IQVIA Holdings Inc

With the stock recently trading near USD 178 on the New York Stock Exchange, IQVIA’s equity value stands at close to USD 29.7 billion, and the shares change hands at a price/earnings ratio of roughly 20.5 based on Robinhood data for the current trading week. That multiple places the United States-listed group in the mid-range of healthcare and life sciences service providers, where investors frequently balance expectations for data-driven growth against regulatory, pricing and spending risks in the broader sector.

MarketBeat’s chart and valuation overview as of 05/28/2026 showed IQVIA’s share price up about 30.5% over the past 12 months but still down roughly 19.7% year-to-date, highlighting that the current P/E ratio is being assessed against a backdrop of significant volatility through the cycle. According to MarketBeat’s competitor and alternative listings, the consensus analyst price target on IQVIA stands around USD 225.69, implying potential upside from current levels, though that figure reflects aggregated sell-side views rather than a firm forecast and may change as new research is published.

Conclusion

IQVIA Holdings Inc remains in focus on the New York Stock Exchange as traders react to the company’s raised 2026 profit outlook and reinforcement of its share repurchase program, factors that have helped the US-listed shares recover part of their earlier year-to-date weakness. Against that backdrop, the current valuation profile, including a price/earnings multiple in the low-20s and a share price that has climbed more than 30% over the past year, underscores how the market is balancing earnings momentum with the risks and opportunities inherent in data-driven healthcare services. Investors will be watching upcoming quarterly results and any further guidance updates for signals on whether IQVIA can sustain its improved profitability trajectory while maintaining disciplined capital allocation.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.